Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis.

Atrash, Shebli; Flahavan, Evelyn M; Xu, Tao; Ma, Esprit; Karve, Sudeep; Hong, Wan-Jen; Jirau-Lucca, Gilbert; Nixon, Michael; Ailawadhi, Sikander

Atrash, Shebli; Flahavan, Evelyn M; Xu, Tao; Ma, Esprit; Karve, Sudeep; Hong, Wan-Jen; Jirau-Lucca, Gilbert; Nixon, Michael; Ailawadhi, Sikander.

Affiliation

Atrash S; Levine Cancer Institute-Morehead (Hematology), Charlotte, NC, USA.
Flahavan EM; Roche Products Ltd, Welwyn Garden City, UK.
Xu T; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Ma E; Genentech, Inc., South San Francisco, CA, USA.
Karve S; AbbVie, Inc., North Chicago, IL, USA.
Hong WJ; Genentech, Inc., South San Francisco, CA, USA.
Jirau-Lucca G; Imago BioSciences, South San Francisco, CA, USA.
Nixon M; Genentech, Inc., South San Francisco, CA, USA.
Ailawadhi S; Genentech, Inc., South San Francisco, CA, USA.

Blood Cancer J ; 12(3): 46, 2022 03 23.

Article in En | MEDLINE | ID: mdl-35322025

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Blood Cancer J Year: 2022 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google